

**IX BIOPHARMA LTD.**  
(Incorporated in the Republic of Singapore)  
Company Registration No. 200405621W

**RESULTS OF THE ANNUAL GENERAL MEETING**

The Board of Directors (the “**Board**”) of iX Biopharma Ltd (“**the Company**”) wishes to announce the results of the resolutions put to vote at the Annual General Meeting held on 14 October 2022 (“**AGM**”), by way of poll voting.

The Board refers to the Company’s Notice of AGM as announced on 22 September 2022 and wishes to inform that Mr Low Weng Keong had retired as a Director of the Company following the conclusion of the AGM. Mr Low’s retirement was also announced via SGXNET on 22 September 2022. The Board and Management wishes to take this opportunity to express their appreciation to Mr Low for his contributions to the Company during his tenure in office.

All resolutions as set out in the Notice of AGM were duly passed.

The statements as required under Rule 704(7) of the Catalist Rules in connection with the re-appointment of directors to the Audit Committee are set out below:

- (i) Mr Patrick Donald Davies, having been re-appointed as a Director of the Company at the AGM, remains as the Lead Independent Director of the Company, the Chairperson of the Remuneration Committee and as a member of the Audit Committee, Nominating Committee and Risk Management Committee. The Board considers Mr Davies to be independent for the purposes of Rule 704(7) of the Catalist Rules;
- (ii) Ms Angeline Tham Xiwen, having been re-appointed as a Director of the Company at the AGM, remains as an Independent Director of the Company, the Chairperson of the Nominating Committee and as a member of the Audit Committee and Remuneration Committee. The Board considers Ms Tham to be independent for the purposes of Rule 704(7) of the Catalist Rules; and
- (iii) The retirement of Mr Low as a Director the Company does not affect the requirement of having at least a minimum of three (3) members on the Company’s Audit Committee. The Audit Committee currently comprise Mr Davies, Ms Tham and Mr Albert Ho Shing Tung. The Board shall update shareholders on the appointment of the Audit Committee Chairperson in due course.

The information as required under Rule 704(15) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”) are set out below:

**(a) Breakdown of all valid votes at the AGM:**

Resolution Number and Details	For		Against		Total Number of Shares Represented by Votes For and Against the relevant resolution
	Number of Shares	As a percentage of total number of votes for and against the resolution (%)	Number of Shares	As a percentage of total number of votes for and against the resolution (%)	
<b>Ordinary Resolution 1</b> Adoption of Directors’ Statement and Audited Financial Statements together with the Auditors’ Report thereon, for the financial year ended 30 June 2022.	441,662,341	100%	0	0%	441,662,341

Resolution Number and Details	For		Against		Total Number of Shares Represented by Votes For and Against the relevant resolution
	Number of Shares	As a percentage of total number of votes for and against the resolution (%)	Number of Shares	As a percentage of total number of votes for and against the resolution (%)	
<b><u>Ordinary Resolution 2</u></b> Re-appointment of Mr Patrick Donald Davies, a Director retiring by rotation in accordance with Regulation 85 of the Company's Constitution and Rule 720(4) of the Catalist Rules.	441,661,841	100%	500	0%	441,662,341
<b><u>Ordinary Resolution 3</u></b> Re-appointment of Ms Angeline Tham Xiwen, a Director retiring by rotation in accordance with Regulation 84 of the Company's Constitution.	441,661,841	100%	500	0%	441,662,341
<b><u>Ordinary Resolution 4</u></b> Payment of Directors' fees of up to S\$334,000 for the financial year ending 30 June 2023, to be paid quarterly in arrears.	441,661,841	100%	500	0%	441,662,341
<b><u>Ordinary Resolution 5</u></b> Re-appointment of Messrs Pricewaterhouse-Coopers LLP as the Company's Auditors and to authorise the Company's Directors to fix their remuneration.	441,661,841	100%	500	0%	441,662,341
<b><u>Ordinary Resolution 6</u></b> Authority to allot and issue Shares.	441,661,841	100%	500	0%	441,662,341
<b><u>Ordinary Resolution 7</u></b> Authority to allot and issue Shares under the iX Employee Share Option Scheme.	441,661,841	100%	500	0%	441,662,341
<b><u>Ordinary Resolution 8</u></b> Authority to allot and issue Shares under the iX Performance Share Plan.	441,661,841	100%	500	0%	441,662,341

*Note: Percentages are calculated and rounded to 2 decimal places.*

**(b) Details of parties who are required to abstain from voting on any resolution(s):**

No party was required to abstain from voting on the resolutions voted at the AGM.

**(c) Name of firm and/or person appointed as scrutineer:**

Janusys Consultants Pte. Ltd. was appointed as scrutineer of the AGM proceedings.

BY ORDER OF THE BOARD

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor  
Company Secretaries

14 October 2022

This announcement has been prepared by iX Biopharma Ltd. (the “Company”) and its contents have been reviewed by the Company’s Sponsor, UOB Kay Hian Private Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.